GHP Family Pharmacy Customer Service
100 N. Academy Ave.
Danville, PA 17822
Tel. • 855•552•6028 PA Relay 711 GeisingerHealthPlan.com

Geisinger

NATALIZUMAB PRIOR AUTHORIZATION FORM *(form effective 1/5/2026)*

Prior authorization guidelines for **Natalizumab** and **Quantity Limits/Daily Dose Limits** are available on Geisinger Health Plan's website at https://healthplan.geisinger.org/pharmacy/pharmacy.aspx?strip=true&style=OneGeisinger.

☐New request ☐Renewal request	total pages: _____	Prescriber name:	
Name of office contact:		Specialty:	
Contact's phone number:		NPI:	State license #:
LTC facility contact/phone:		Street address:	
Beneficiary name:		City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Drug requested:	Strength:	Quantity: _____ vials	Refills:
Directions: ☐300 mg SQ every 4 weeks		☐other: _____	
Diagnosis *(submit documentation)*:		Dx code *(required)*:	
Is the beneficiary currently being treated with the requested medication?	☐Yes – date of last dose: _____ *Submit documentation.* ☐No		
Is natalizumab prescribed by or in consultation with a neurologist or gastroenterologist?	☐Yes ☐No	*Submit documentation of consultation if applicable.*	
Is the beneficiary receiving chronic immunosuppressive or immune modulating therapies?	☐Yes ☐No	*Submit complete medication list.*	

Complete all sections that apply to the beneficiary and this request.

Check all that apply and submit documentation for each item.

INITIAL requests

1. For treatment of MULTIPLE SCLEROSIS (MS):

☐Has a relapsing form of MS

2. For treatment of CROHN'S DISEASE (CD):

☐Has moderate-to-severe CD
☐Has CD that is associated with high-risk or poor prognostic features
☐Has achieved remission with the requested medication AND:
  ☐Will be using the requested medication as maintenance therapy to maintain remission
☐Tried and failed a TNF-inhibitor (e.g., Cimzia, Humira, Remicade) or has a contraindication or an intolerance to TNF-inhibitors
☐Tried and failed an IL-12/23 or IL-23 inhibitor (e.g., Skyrizi, Stelara, Tremfya) or has a contraindication or an intolerance to IL-12/23 and IL-23 inhibitors
☐Tried and failed or has a contraindication or intolerance to vedolizumab (Entyvio)

GHP Family Pharmacy Customer Service
100 N. Academy Ave.
Danville, PA 17822
Tel. • 855•552•6028 PA Relay 711 GeisingerHealthPlan.com

Geisinger

3. For a NON-PREFERRED natalizumab product:

☐ Has a history of trial and failure of or a contraindication or an intolerance to the preferred natalizumab product(s) approved or medically accepted for the beneficiary's diagnosis

RENEWAL requests

1. For treatment of MULTIPLE SCLEROSIS (MS):

☐ Experienced improvement or stabilization of the MS disease course since starting natalizumab

2. For treatment of CROHN'S DISEASE:

☐ Experienced therapeutic benefit within 3 months of starting natalizumab
☐ Was able to discontinue concomitant steroid use within 6 months of starting natalizumab (if applicable)
☐ **Has been using natalizumab for at least 1 year AND:**
  ☐ Has not required additional steroid use for disease control for more than 3 months in the past 12 months

3. For a NON-PREFERRED natalizumab product:

☐ Has a history of trial and failure of or a contraindication or an intolerance to the preferred natalizumab product(s) approved or medically accepted for the beneficiary's diagnosis

Please submit to PromptPA https://ghp.promptpa.com
OR fax to Geisinger Health Plan at 570-271-5610 the completed form with required clinical documentation.

Prescriber Signature:	**Date**: